Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Biomarkers tested Fasting lipid panel LDL Homocysteine HDL Total cholesterol Triglycerides hs-CRP Apolipoprotein B (ApoB) Lipoprotein(a) Glucose & insulin Homocysteine level Treatments offered Long term benefits Lower heart attack risk Slowed progression of atherosclerosis Improved blood pressure Lower heart attack risk Healthier cholesterol levels Enhanced exercise capacity and energy Increased longevity and quality of life We detect imbalances like insulin resistance long before diabetes develops
Recommendations for reporting metabolite data
The results, by dose: For context: in the equivalent Phase 2 trials, semaglutide produced about 14.9% weight loss at the highest dose, and tirzepatide produced about 20.9%
For anyone whose hesitation comes down to the needle itself, the learning curve is short
